Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
Pharma News
First of Amgen’s Phase III Sjögren’s disease trials succeeds in new study
Amgen’s Phase III Sjögren’s disease trial met its primary endpoint, showing a significant reduction in systemic disease activity using dazodalibep.
Why Do Clinical Trials for Cancer Drugs Take So Long? - Readers Respond
Readers respond to a guest essay concerning the costs and delays in getting experimental cancer treatments to patients, highlighting rigorous safety needs.
Creative Biolabs Announces Therapeutic Antibody Engineering Services
Creative Biolabs has launched a suite of therapeutic antibody engineering services to help biopharma address preclinical challenges in safety and efficacy.
Eli Lilly Expands China Biotech Strategy With $3.25B InnoCare Partnership
Eli Lilly and InnoCare Pharma signed a strategic $3.25 billion collaboration to discover and develop compounds targeting critical unmet medical needs globally.
Merck KGaA's $11.3B Bio-Techne Acquisition Clears Shareholder Vote Hurdle
Bio-Techne shareholders have approved Merck KGaA's $11.3 billion acquisition offer, clearing a major hurdle following the HSR antitrust waiting period expiry.
Zymeworks Completes $929M Acquisition of Theravance Biopharma Operations
Zymeworks acquired Theravance Biopharma for $929 million, expanding its portfolio with the commercial-stage respiratory asset revefenacin and royalty streams.
Tvardi's STAT3 Inhibitor Shows Preclinical Promise for Ulcerative Colitis
New preclinical data published in IJMS highlights the potential of Tvardi Therapeutics' oral STAT3 inhibitor, TTI-101, to prevent colitis-associated cancer.
Earendil Secures $1.5B Genentech Deal for AI-Designed Oncology Antibodies
Earendil Labs signs a $1.5B+ deal with Genentech to discover and develop AI-designed bispecific antibodies for oncology, including a $55M upfront payment.
Anacalypsis Secures Seed Funding for Novel Parkinson's Disease Treatment
Greek startup Anacalypsis raised pre-seed funding to advance AT001, a stapled peptide targeting LRRK2-FADD interactions for Parkinson's disease treatment.
Preclinical Parkinson's Study: Chlorogenic Acid Fails to Show Protection
A Cure Parkinson's funded study at IISER Thiruvananthapuram found that chlorogenic acid does not provide neuroprotective effects in Parkinson's models.
J&J's Icotyde Secures EU Approval for Moderate-to-Severe Plaque Psoriasis
The European Commission has approved J&J’s oral IL-23 receptor antagonist ICOTYDE for adults and adolescents with moderate-to-severe plaque psoriasis.
FDA Updates Regulations to Advance Alternatives for Animal Drug Testing
The FDA updated regulations to allow non-animal methods like organs-on-chips and AI models for human drug safety testing to complement animal studies.
1
2
3
4
5
6
